Novel Approaches in the Systemic Management of High-Risk Prostate Cancer

Clin Genitourin Cancer. 2023 Jun 18:S1558-7673(23)00140-4. doi: 10.1016/j.clgc.2023.06.001. Online ahead of print.ABSTRACTLocally advanced prostate cancer comprises approximately 20% of new prostate cancer diagnoses. For these patients, international guidelines recommend treatment with radiotherapy (RT) to the prostate in combination with long-term (2-3 years) androgen deprivation therapy (ADT), or radical prostatectomy in combination with extended pelvic lymph node dissection (PLND) as another treatment option for selected patients as part of multimodal therapy. Improvements in overall survival with docetaxel or an androgen receptor signaling inhibitor have been achieved in patients with metastatic castration sensitive or castration resistant prostate cancer. However, the role of systemic therapy combinations for high risk and/or unfavorable prostate cancer is unclear. In this context, the aim of this review is to assess the current evidence for systemic treatment combinations as part of primary definitive therapy in patients with high-risk localized prostate cancer.PMID:37453915 | DOI:10.1016/j.clgc.2023.06.001
Source: Clinical Prostate Cancer - Category: Cancer & Oncology Authors: Source Type: research